Marksans Pharma Q1 FY27 Results: Revenue Rs 840 Cr, PAT Rs 159 Cr and Key Highlights
- August 13, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Marksans Pharma Q1 FY27: Revenue Rs 840 Cr (+35.61% YoY). PAT Rs 159 Cr (+173.89% YoY). Results August 12, 2026. CMP Rs 309.50.
Quick Answer
Marksans Pharma reported a 174% jump in net profit to Rs 159 crore in Q1 FY27, compared with Rs 58 crore in the same quarter last year. Revenue climbed 36% to Rs 840 crore during the June 2026 quarter, with gross profit expanding significantly to Rs 188 crore. The Marksans Pharma Q1 FY27 results reflect solid operating momentum within the Pharmaceuticals sector.
Marksans Pharma Q1 FY27 results were declared on August 12, 2026, with the pharmaceuticals company reporting a net profit (PAT) of Rs 159 crore, up 173.89% from Rs 58 crore in Q1 FY26. The figures are on a consolidated basis for the quarter ended June 30, 2026.
The June 2026 quarter saw sharp growth in Marksans Pharma’s revenue, which climbed 36% year on year to Rs 840 crore. Gross profit for the period stood at Rs 188 crore, up from Rs 77 crore a year earlier.
Click Here – Get Free Investment Predictions
Marksans Pharma Q1 FY27 Financial Highlights
The table below breaks down the key financial figures from the Marksans Pharma Q1 FY27 results against Q1 FY26.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | Rs 840 Cr | Rs 619 Cr | +35.61% |
| Gross Profit (Rs Cr) | Rs 188 Cr | Rs 77 Cr | +144.31% |
| Net Profit / (Loss) – PAT (Rs Cr) | Rs 159 Cr | Rs 58 Cr | +173.89% |
Marksans Pharma Q1 FY27 Results Performance Analysis
Use the Univest Screener to Track Live Fundamentals of Indian Stocks
The Marksans Pharma Q1 FY27 results show revenue growth of 35.61% year on year to Rs 840 crore. Gross profit improved to Rs 188 crore from Rs 77 crore in Q1 FY26.
Net profit in the June 2026 quarter stood at Rs 159 crore, up 173.89% from Rs 58 crore in Q1 FY26. Investors should verify all figures against the company’s official filings on BSE and NSE.
Key Business Factors in Marksans Pharma Q1 FY27
1. Revenue Growth Expanded the Top Line
35.61% revenue growth year on year reflects strengthening demand in the Pharmaceuticals segment. The June 2026 quarter benefited from higher volumes and improved pricing.
2. Gross Profit Trend
Gross profit rose to Rs 188 crore from Rs 77 crore in Q1 FY26. Better raw material costs and pricing power supported the improvement.
3. Net Profit Rose Quarter on Quarter
Net profit came in at Rs 159 crore, up 173.89% from Rs 58 crore in Q1 FY26. The double-digit profit growth signals solid earnings quality in the current business cycle.
Dividend Details
No dividend has been announced along with the Marksans Pharma Q1 FY27 results for the quarter ended June 2026. Investors can check future dividend updates on BSE and NSE.
Marksans Pharma FY27 Outlook After Q1 Results
The June 2026 quarter results lay a reasonable foundation for FY27. Revenue growth of 35.61% combined with a net profit (PAT) of Rs 159 crore shows the company is firing on most cylinders. Investors tracking the Marksans Pharma Q1 FY27 results should watch for management commentary on demand trends in Pharmaceuticals, raw material cost outlook, and any capex or expansion plans that could shape FY27 earnings.
Marksans Pharma Stock Performance
Download the Univest iOS App or Univest Android App to track Marksans Pharma share price and upcoming results.
Marksans Pharma shares were trading at Rs 309.50 on August 12, 2026, the day the Pharmaceuticals company announced its Q1 FY27 results. Post-results price action will depend on how the market interprets the revenue and profit trajectory. Always check the latest price on NSE and BSE before making any investment decision.
Key Risks After Marksans Pharma Q1 FY27 Results
1. Demand Slowdown in Pharmaceuticals
A pullback in Pharmaceuticals demand could weigh on revenue growth and make it harder to sustain the profitability levels seen in Q1 FY27.
2. Input Cost and Margin Pressure
Rising raw material costs or an unfavourable sales mix could squeeze gross margins and limit net profit improvement through the rest of FY27.
3. Macro and Regulatory Headwinds
Broader factors such as interest rate movements, currency volatility, and sector-specific regulatory changes remain risks to watch for the remainder of FY27.
Conclusion
The Marksans Pharma Q1 FY27 results show revenue of Rs 840 crore and a net profit (PAT) of Rs 159 crore, up 173.89% from Rs 58 crore in Q1 FY26. The performance reflects the company’s current standing in the Pharmaceuticals space. Investors should go through the detailed financial statements on BSE and NSE and seek advice from a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Marksans Pharma Q1 FY27 Results
When were the Marksans Pharma Q1 FY27 results announced?
Ans. The Marksans Pharma Q1 FY27 results were announced on August 12, 2026. The consolidated financials cover the quarter ended June 30, 2026, and were filed with the BSE and NSE on the same date.
What was the net profit in the Marksans Pharma Q1 FY27 results?
Ans. Net profit (PAT) stood at Rs 159 crore in Q1 FY27, up 173.89% from Rs 58 crore in Q1 FY26.
What was the revenue in the Marksans Pharma Q1 FY27 results?
Ans. Revenue for the June 2026 quarter grew 35.61% year on year to Rs 840 crore from Rs 619 crore in Q1 FY26.
Did Marksans Pharma declare a dividend with Q1 FY27 results?
Ans. No dividend has been declared alongside the Marksans Pharma Q1 FY27 results for the June 2026 quarter. Any future dividend announcements will be available on the BSE and NSE portals.
What is the FY27 outlook for Marksans Pharma after Q1 results?
Ans. The June 2026 quarterly performance signals a positive trajectory for FY27. Key factors to watch include demand trends in the Pharmaceuticals sector, margin performance, and management guidance for the year.
Is Marksans Pharma a good stock to buy after Q1 FY27 results?
Ans. The Q1 FY27 results of Marksans Pharma provide insight into the company’s financial health, but investment decisions should never be based on one quarter alone. This article is for educational purposes and does not constitute investment advice. Please consult a SEBI-registered advisor before making any investment decision.
